SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Pfizer Inc. (PFE) trades at a trailing P/E of 20.1, forward P/E of 9.2. Trailing earnings yield is 4.99%, forward earnings yield 10.89%. PEG 0.08 (Peter Lynch undervalued ≤1.0). Graham Number is $21.67.
Criteria proven by this page:
- VALUE (61/100, Pass) — P/E is below market average (20.1); PEG ≤ 1.0 — Peter Lynch undervalued (0.08); earnings yield beats bond yields (4.99%).
- Forward P/E 9.2 (down from trailing 20.1) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.08 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 4.99% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 10.89% as earnings recover.
- Analyst consensus target $27.50 (+1.4% upside) — modest upside expected.
Overall SharesGrow Score: 65/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
61/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — PFE
Valuation Multiples
P/E (TTM)20.1
Forward P/E9.2
PEG Ratio0.08
Forward PEG0.08
P/B Ratio1.80
P/S Ratio2.49
EV/EBITDA13.2
Per Share Data
EPS (TTM)$1.37
Forward EPS (Est.)$2.96
Book Value / Share$15.27
Revenue / Share$11.01
FCF / Share$1.60
Yields & Fair Value
Earnings Yield4.99%
Forward Earnings Yield10.89%
Dividend Yield6.27%
Graham Number$21.67
SharesGrow IV$17.48 (-35.6%)
Analyst Target$27.50 (+1.4%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
26.0 |
5.61 |
3.15 |
3.55 |
3.90% |
| 2017 |
9.6 |
0.05 |
2.87 |
3.90 |
3.74% |
| 2018 |
21.8 |
-0.47 |
3.83 |
4.53 |
3.28% |
| 2019 |
12.7 |
0.24 |
3.28 |
5.02 |
3.89% |
| 2020 |
22.3 |
-0.51 |
3.23 |
4.91 |
4.13% |
| 2021 |
14.9 |
0.11 |
4.28 |
4.07 |
2.64% |
| 2022 |
9.2 |
0.22 |
3.00 |
2.86 |
3.13% |
| 2023 |
76.2 |
-0.82 |
1.83 |
2.73 |
5.69% |
| 2024 |
18.7 |
0.07 |
1.70 |
2.36 |
6.33% |
| 2025 |
18.2 |
-4.31 |
1.64 |
2.26 |
6.91% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$1.17 |
$52.82B |
$7.22B |
13.7% |
| 2017 |
$3.52 |
$52.55B |
$21.31B |
40.6% |
| 2018 |
$1.87 |
$53.65B |
$11.15B |
20.8% |
| 2019 |
$2.87 |
$51.75B |
$16.27B |
31.4% |
| 2020 |
$1.25 |
$41.91B |
$7.02B |
16.8% |
| 2021 |
$3.88 |
$81.29B |
$21.98B |
27% |
| 2022 |
$5.47 |
$100.33B |
$31.37B |
31.3% |
| 2023 |
$0.37 |
$58.5B |
$2.12B |
3.6% |
| 2024 |
$1.41 |
$63.63B |
$8.03B |
12.6% |
| 2025 |
$1.36 |
$62.58B |
$7.77B |
12.4% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$2.96 |
$2.87 – $3.06 |
$61.19B |
$60.32B – $62.09B |
15 |
| 2027 |
$2.82 |
$2.64 – $2.95 |
$58.86B |
$56.86B – $60.73B |
15 |
| 2028 |
$2.45 |
$1.61 – $2.90 |
$54.76B |
$54.62B – $54.91B |
8 |
| 2029 |
$2.17 |
$2.10 – $2.25 |
$51.66B |
$50.3B – $53.11B |
6 |
| 2030 |
$2.22 |
$2.14 – $2.30 |
$51.8B |
$50.42B – $53.25B |
6 |
